{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+50%25", "query": { "intervention": "Carbohydrate 50%" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 731, "total_pages": 74, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+50%25&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T07:51:00.377Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04246996", "title": "Gentamicin Intravesical Efficacy for Infection of Urinary Tract", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Postoperative Urinary Tract Infection", "Pelvic Organ Prolapse", "Stress Urinary Incontinence" ], "interventions": [ { "name": "gentamicin sulfate", "type": "DRUG" }, { "name": "Catheter clamping only", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 370, "start_date": "2020-01-29", "completion_date": "2021-12-05", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-09-09T07:51:00.377Z", "location_count": 2, "location_summary": "La Jolla, California • San Diego, California", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04246996" }, { "nct_id": "NCT01148979", "title": "Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Lisdexamfetamine Dimesylate (Vyvanse)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mclean Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 35, "start_date": "2010-09", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-05-23", "last_synced_at": "2026-09-09T07:51:00.377Z", "location_count": 1, "location_summary": "Belmont, Massachusetts", "locations": [ { "city": "Belmont", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01148979" }, { "nct_id": "NCT00387868", "title": "Preoperative Treatment of Patients With High Risk Thymoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thymoma" ], "interventions": [ { "name": "cisplatin and etoposide", "type": "DRUG" }, { "name": "Surgical Resection", "type": "PROCEDURE" }, { "name": "Concurrent Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Valley Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2006-10", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2014-12-09", "last_synced_at": "2026-09-09T07:51:00.377Z", "location_count": 1, "location_summary": "Ridgewood, New Jersey", "locations": [ { "city": "Ridgewood", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00387868" }, { "nct_id": "NCT01489917", "title": "A-priori Versus Provisional Heparin on Radial Artery Occlusion After Transradial Coronary Angiography and Patent Hemostasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Patent hemostasis and heparin", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Olivier F. Bertrand", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 428, "start_date": "2009-05", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2012-05-08", "last_synced_at": "2026-09-09T07:51:00.377Z", "location_count": 1, "location_summary": "Scranton, Pennsylvania", "locations": [ { "city": "Scranton", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01489917" }, { "nct_id": "NCT00126191", "title": "Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Burkitt Lymphoma", "Non-Hodgkins Lymphoma", "Atypical Burkitt Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2005-07", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2013-05-23", "last_synced_at": "2026-09-09T07:51:00.377Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00126191" }, { "nct_id": "NCT02494479", "title": "Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Prurisol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellceutix Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2015-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2017-07-19", "last_synced_at": "2026-09-09T07:51:00.377Z", "location_count": 9, "location_summary": "Huntsville, Alabama • Encino, California • Coral Gables, Florida + 5 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Encino", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Kissimmee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02494479" }, { "nct_id": "NCT04354428", "title": "Treatment for COVID-19 in High-Risk Adult Outpatients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19", "SARS-CoV-2" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DRUG" }, { "name": "Hydroxychloroquine Sulfate", "type": "DRUG" }, { "name": "Azithromycin", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" }, { "name": "Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 289, "start_date": "2020-04-16", "completion_date": "2020-11-30", "has_results": true, "last_update_posted_date": "2022-08-08", "last_synced_at": "2026-09-09T07:51:00.377Z", "location_count": 6, "location_summary": "Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Syracuse", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04354428" }, { "nct_id": "NCT05545306", "title": "The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Normal Physiology", "Healthy Volunteers" ], "interventions": [ { "name": "+200% of dietary requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat", "type": "DIETARY_SUPPLEMENT" }, { "name": "fasting", "type": "DIETARY_SUPPLEMENT" }, { "name": "-50% of energy balance requirements. 50% of calories from carbohydrates, 20% from protein, and 30% from fat", "type": "DIETARY_SUPPLEMENT" }, { "name": "+150% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat", "type": "DIETARY_SUPPLEMENT" }, { "name": "+200% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein", "type": "DIETARY_SUPPLEMENT" }, { "name": "-25% of energy balance requirements, 50% of calories from carbohydrates, 20% from protein, and 30% from fat", "type": "DIETARY_SUPPLEMENT" }, { "name": "+150% of dietary requirements, 51% of the calories from carbohydrates, 46%, from fat and 3% from protein", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 120, "start_date": "2023-06-06", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-09T07:51:00.377Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05545306" }, { "nct_id": "NCT01454622", "title": "A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)", "type": "DRUG" }, { "name": "B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 64, "start_date": "2011-09", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2013-05-06", "last_synced_at": "2026-09-09T07:51:00.377Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01454622" }, { "nct_id": "NCT01815294", "title": "A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Neoplasms, Ovarian", "Neoplasms, Breast", "Advanced or Refractory Solid Malignancies" ], "interventions": [ { "name": "DOXIL/CAELYX (doxorubicin) Treatment Sequence AB", "type": "DRUG" }, { "name": "DOXIL/CAELYX (doxorubicin) Treatment Sequence BA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2013-05", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-09-09T07:51:00.377Z", "location_count": 2, "location_summary": "Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01815294" } ] }